Where does Eloxx Pharmaceuticals Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Eloxx Pharmaceuticals Ltd. ranks #35,166 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Eloxx Pharmaceuticals Ltd. hold?

Eloxx Pharmaceuticals Ltd. holds 7 US utility patents granted between 2020 and 2023, spanning 4 technology areas.

What is Eloxx Pharmaceuticals Ltd.'s Innovation Score?

Eloxx Pharmaceuticals Ltd. has an Innovation Score of 30.1 out of 100 (33rd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Eloxx Pharmaceuticals Ltd. focus on?

Eloxx Pharmaceuticals Ltd.'s top technology area is C07H (SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids) with 6 patents, ranking #156 of 896 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

Is Eloxx Pharmaceuticals Ltd.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Eloxx Pharmaceuticals Ltd..

What does claim depth mean for Eloxx Pharmaceuticals Ltd.'s patents?

Eloxx Pharmaceuticals Ltd.'s patents average 18.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Eloxx Pharmaceuticals Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Eloxx Pharmaceuticals Ltd.

USPTO PatentsView assignee record - 7 granted patents across 4 technology areas, recorded in grant years 2020–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07H (SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Eloxx ranks #35,166 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 4 technology areas.

#35,166
of 49,997 US assignees by volume: 33rd percentile
by Innovation Score (30.1/100): 18.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R35166 · Foreign Corporation #35,166 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 7 grants
MID-PACK #35,166/49,997
PHOTO-FINISH Eley
CPC-NARROW C07H · 4 areas
INNOV-THIN 30.1/100
CLAIMS-RICH 18.0 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2020–2023 · 4y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Eley Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Eloxx’s 30.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.2 pts (24%) Velocity 5.0 pts (17%) Breadth 7.1 pts (24%) Claim depth 10.8 pts (36%)

Qualcomm Incorporated · highest

85
Eloxx Pharmaceuticals · this assignee

30
3D Lighting… · lowest

7

What this shows Eloxx's Innovation Score is 30.1/100 (33rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Eloxx?

Each dot is one of Eloxx’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Eloxx’s own 18.0 claims/patent is ABOVE the 15.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Eloxx vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Eloxx's grants concentrate

Eloxx Pharmaceuticals Ltd. is a focused PatentsView assignee: 4 CPC subclasses with 85.7% of grants classified under C07H (SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids). Peak complete grant year is 2020 (2 grants) versus a trough of 1 in 2022. By volume, Eloxx sits between Eley Corporation and Emfit OY.

Eloxx's three-year grant acceleration

Eloxx Pharmaceuticals Ltd. shows 3 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Eley

7
Elika Access Syst…

7
Ellex Medical PTY

7
Ellis Patents (Ho…

7
Elyse Enterprises

7
Embr Labs IP

7
Emefcy

7
Emfit OY

7
Eloxx Pharmaceuti… ◀

7

What this shows Eloxx holds 7 patents at rank #35,131, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Eloxx

By rank, the assignees closest to #35,131 in granted patent volume.

Leaders in C07H (Sugars)

Other assignees with the most granted patents in Eloxx's primary technology class.

Eloxx's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

30 33rd percentile higher than 33% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Eloxx Pharmaceuticals Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	2	28.6%
2021	2	28.6%
2022	1	14.3%
2023	2	28.6%

Which technologies does Eloxx Pharmaceuticals Ltd. patent most?

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 6

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 3

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 1

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Eloxx Pharmaceuticals Ltd.'s patent record in context - here's where to go next.

Eloxx Pharmaceuticals Ltd.'s lead technology class is C07H (SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids), 85.7% of its portfolio - see every assignee active in that class. Explore C07H
Ranked #35,166 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Eloxx Pharmaceuticals Ltd. against Eley Corporation, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 30.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.